28 Results
Sort By:
Published on July 19, 2024
Possibly adding a new entrant to the highly competitive diabetes/weight loss market, Roche has announced positive interim results from an ongoing Phase I trial for its oral small molecule GLP-1 receptor agonist, CT996. The drug is being developed for both type 2 diabetes and obesity, and the company says treatment…
Published on May 16, 2024
A novel, bimodal, drug that affects neuroplasticity causes twice the amount of weight loss in obese mice than a GLP-1 agonist alone, researchers have shown. The drug, MK-801, integrates N-methyl-D-aspartate (NMDA) antagonism with glucagon-like peptide-1 (GLP-1) agonism. In mice, it reverses obesity, hyperglycemia and dyslipidemia. The drug’s developers believe that,…
Published on April 11, 2024
In a comprehensive study spanning three Scandinavian countries, researchers from the Karolinska Institute in Sweden have found no significant link between the use of GLP-1 analogues, a popular class of diabetes drugs, and an increased risk of thyroid cancer. Published in The BMJ, the study aims to put to rest…
Published on November 9, 2023
AstraZeneca has licensed ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA), from Eccogene for the treatment of obesity, type 2 diabetes, and other cardiometabolic conditions. Eccogene will receive an initial upfront payment of $185M and up to $1.825B in future clinical, regulatory, and commercial milestones and tiered…
Published on July 10, 2024
A study of more than 1.5 million people with type 2 diabetes has shown that individuals using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have a significantly lower risk for obesity-associated cancers (OACs) than those using insulin. The findings “provide preliminary evidence of the potential benefit of GLP-1 RAs for cancer…
Published on November 11, 2024
In a preliminary study set to be presented at the American Heart Association’s Scientific Sessions 2024, a team of researchers from the Mayo Clinic in Rochester, Minnesota, found that GLP-1 receptor agonists and SGLT2 inhibitors may significantly reduce the risk of heart attacks, second strokes, and death in adults who…
Published on September 13, 2024
A recent Cleveland Clinic study has shed light on the critical factors influencing long-term weight loss in patients with obesity prescribed GLP-1 receptor agonist (RA) medications like semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda, Victoza). These drugs, widely used to lower blood sugar and promote weight loss in individuals with type…
Published on June 27, 2023
Results presented at the annual American Diabetes Association conference show Eli Lilly’s retatrutide was able to induce up to a 24 percent reduction in body weight in individuals with obesity during almost a year of follow-up in a Phase II trial. As reported in the New England Journal of Medicine…
Published on October 18, 2024
Phenomix Sciences, a biotech focusing on obesity phenotyping and biomarker testing, will partner with genetic testing and counseling provider InformedDNA to provide targeted obesity treatment based on underlying biology. Obesity is a very heterogeneous condition that can manifest for many different reasons. The approval of Novo Nordisk’s GLP-1 agonist Wegovy (semaglutide) for…
Published on August 14, 2024
There’s a new weight loss drug candidate in town, and it’s targeted specifically at obese heart patients. Rivus Pharmaceuticals’ HU6 led to statistically significant weight loss in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) in a mid-stage trial (the HuMAIN study). HFpEF patients have symptoms of HF,…
Published on July 18, 2024
Using drugs to “prime” the melanocortin system could improve the effectiveness, without increasing side effects, of popular diabetes and weight-loss medications, according to new research from the University of Michigan. In one study, mice given a GLP-1 drug in combination with an MC4R agonist or MC3R antagonist showed up to…
Published on June 5, 2024
A report published in 2023, estimates that over 40% of adults in the U.S. have obesity, defined as a body mass index (BMI) of over 30 kg/m2. While not everyone in this group is unwell, there is no doubt that obesity increases the risk of associated health conditions such as…
Published on April 22, 2024
“Next generation” weight loss drug developer Metsera just launched with $290M in funding. Backed by Population Health Partners and ARCH Venture Partners and led by former executives of The Medicines Company, Metsera has a broad portfolio of oral and injectable incretin, non-incretin, and combination therapies designed to address multiple targets.…
Published on March 11, 2024
Novo Nordisk has just taken two big steps toward cementing its lead in the weight loss treatment market. Late last week, the FDA approved a new label expansion for Wegovy (semaglutide), and just before that the company released promising early trial results for its experimental weight loss pill, amycretin. Patients…
Published on March 5, 2024
Novo Nordisk today announced it has notched another win for its GLP-1 agonist semaglutide (Ozempic), this time for reducing cardiovascular disease and slowing kidney disease in diabetic patients. The latest results from the FLOW trial suggest the drug cuts risk of death in this population by as much as 24%. …